Mesenchymal Stem Cells-Derived Exosomes Alleviate Acute Lung Injury By Inhibiting Alveolar Macrophage Pyroptosis

Peipei Liu,Shengnan Yang,Xuecheng Shao,Chen Li,Zai Wang,Huaping Dai,Chen Wang
DOI: https://doi.org/10.1093/stcltm/szad094
2024-02-13
Stem Cells Translational Medicine
Abstract:Abstract Acute lung injury (ALI) is an important pathological process of acute respiratory distress syndrome, yet there are limited therapies for its treatment. Mesenchymal stem cells-derived exosomes (MSCs-Exo) have been shown to be effective in suppressing inflammation. However, the effects of MSCs-Exo on ALI and the underlying mechanisms have not been well elucidated. Our data showed that MSCs-Exo, but not exosomes derived from MRC-5 cells (MRC-5-Exo), which are human fetal lung fibroblast cells, significantly improved chest imaging, histological observations, alveolocapillary membrane permeability, and reduced inflammatory response in ALI mice model. According to miRNA sequencing and proteomic analysis of MSCs-Exo and MRC-5-Exo, MSCs-Exo may inhibit pyroptosis by miRNAs targeting caspase-1-mediated pathway, and by proteins with immunoregulation functions. Taken together, our study demonstrated that MSCs-Exo were effective in treating ALI by inhibiting the pyroptosis of alveolar macrophages and reducing inflammation response. Its mechanism may be through pyroptosis-targeting miRNAs and immunoregulating proteins delivered by MSCs-Exo. Therefore, MSCs-Exo may be a new treatment option in the early stage of ALI.
cell & tissue engineering
What problem does this paper attempt to address?
The paper attempts to address the challenge of treating acute lung injury (ALI). Specifically, the study aims to investigate whether mesenchymal stem cell-derived exosomes (MSCs-Exo) can alleviate ALI by inhibiting pyroptosis in alveolar macrophages and to explore the underlying mechanisms. ### Background and Problem - **Acute Lung Injury (ALI)**: ALI is a critical pathological process of acute respiratory distress syndrome (ARDS), with limited treatment options and high mortality rates. - **Mesenchymal Stem Cell-Derived Exosomes (MSCs-Exo)**: MSCs-Exo are known to have anti-inflammatory effects, but their impact on ALI and the underlying mechanisms remain unclear. ### Research Objectives - **Evaluate the efficacy of MSCs-Exo on ALI**: Using a mouse model, the study investigates whether MSCs-Exo can improve ALI symptoms, such as reducing inflammatory responses and decreasing alveolar-capillary membrane permeability. - **Explore the mechanisms**: Through miRNA sequencing and proteomics analysis, the study aims to reveal how MSCs-Exo inhibit pyroptosis in alveolar macrophages by targeting pyroptosis-related miRNAs and immunoregulatory proteins. ### Key Findings - **MSCs-Exo significantly improve ALI symptoms**: In an LPS-induced ALI mouse model, MSCs-Exo significantly improved chest imaging results, histological observations, alveolar-capillary membrane permeability, and inflammatory responses. - **Inhibition of pyroptosis**: MSCs-Exo reduce inflammation by inhibiting the caspase-1-mediated pyroptosis pathway, decreasing the expression of proteins such as NLRP3, caspase-1, GSDMD, IL-1β, and IL-18. - **Dose-dependency**: The therapeutic effect of MSCs-Exo is dose-dependent, with higher doses showing better efficacy. ### Conclusion - **MSCs-Exo as a potential ALI treatment**: By inhibiting pyroptosis in alveolar macrophages, MSCs-Exo can effectively alleviate ALI symptoms and reduce inflammatory responses, potentially becoming a new option for early ALI treatment. ### Significance - **New therapeutic target**: Pyroptosis in alveolar macrophages may be a new target for ALI treatment. - **Clinical application prospects**: Due to their low immunogenicity and ease of preparation, MSCs-Exo hold promise for future clinical treatment of ALI.